Stock Analysis
ABBVIE INC.ABBV
P/E 79.93×· 5Y range 17.79–181.34×· 79th percentile of history
Sector: Healthcare · Industry: Drug Manufacturers - General
AnalystsStrong Buy39 analystsP/E 79.9× sits at the 79th percentile of its 5.089664613278576-year history.
Cash covers 9% of debt · Q2 2026.
PMP Verdict
Mixed fundamentals, expensive valuation
Strengths
- Quality95
Risks
- Valuation34
- Growth31
Mixed fundamentals at a demanding price.
Bull Case
- ✓Piotroski F-Score 8/9 — high earnings quality
What's happening with ABBV
Profile
Strong earnings quality and moat; growth, valuation and financial health lag behind.
How is each axis scored?
- Valuation34/100 · Weak
- P/E vs own history (79th pct)5/25
- FCF yield (3.6%)12/25
- P/S (7.8x)12/25
- EV/EBIT (33.8x)5/25
- Growth31/100 · Weak
- Revenue CAGR (2.1%)6/25
- Net income CAGR (-22.2%)0/25
- EPS CAGR 5Y (-22.2%)0/25
- Fwd implied growth (372.9%)25/25
- Profitability58/100 · Moderate
- ROIC (22.8%)20/25
- ROE (n/a)0/25
- Net margin (9.8%)13/25
- Operating margin (26.2%)25/25
- Financial Health39/100 · Weak
- Altman Z (2.37)18/25
- Current ratio (0.81)6/25
- Interest coverage (3.5x)10/25
- Net cash / debt (D/A 48%)5/25
- Quality95/100 · Strong
- Piotroski F (8/9)25/25
- Beneish M (-2.85)25/25
- FCF conversion (289%)25/25
- Margin stability (σ 7.0%)20/25
- Moat88/100 · Strong
- ROIC >12% years (8/10 yrs)20/25
- Median gross margin (70.1%)25/25
- FCF-positive years (10/10 yrs)25/25
- Worst-year net margin (worst 6.9%)18/25
About ABBVIE INC.
AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). Show more
The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan added several new products and drugs in aesthetics, including Botox. The 2024 acquisitions of Cerevel (neuroscience) and ImmunoGen (oncology) help supplement AbbVie's portfolio.
Headquarters: NORTH CHICAGO, IL · Employees: 57,000 · Website ↗
Price History
Weekly Candlestick Chart — up to 5Y
Key Metrics
Financial snapshot · Tap any metric for its definition and grade
TTM Snapshot
trailing twelve months · YoYValuation
34DP/E (TTM)80.1xD
Grade D: ExpensivePrice / TTM EPS (own statements) — vs own 5Y history: 17.8x–181.3x · 79th pct
P/FCF27.5xB
Grade B: FairPrice / Free Cash Flow per share (Finnhub). Inverse of FCF yield — negative when FCF is negative
FCF Yield3.6%C
Grade C: LowTTM (OCF − CapEx) / Market Cap — vs own 5Y history: 3.6%–11.4% · lowest in history
P/S (TTM)7.85xC
Grade C: ExpensivePrice / TTM Revenue (own statements) — vs own 5Y history: 3.5x–7.8x · highest in history
EV/EBIT33.8xD
Grade D: ExpensiveEnterprise value / TTM EBIT (D&A not in our data) — capital-structure neutral — vs own 5Y history: 15.2x–54.7x · 80th pct
EV/Sales8.8xC
Grade C: ExpensiveEnterprise Value / TTM Revenue (Finnhub) — capital-structure neutral sales multiple
Forward P/E16.9xB
Grade B: FairPrice / next-year EPS estimate — shows whether the TTM multiple is rich or just front-loading growth
P/B RatioNeg. EquityC
Grade C: BuybacksPrice to Book Value. Neg. equity = heavy buybacks
PEG Ratio3.49D
Grade D: ExpensiveFinnhub PEG — their P/E basis ÷ expected EPS growth. Suppressed when their P/E diverges >2× from our TTM P/E (different basis)
Dividend Yield2.39%A
Grade A: PaysTTM dividend yield (Finnhub) — annual dividends / price. None = no dividend; very high yield can signal distress
Payout Ratio189.8%D
Grade D: UnsustainableDividends / Net Income (Finnhub) — share of earnings paid out; >90% or negative = unsustainable
Profitability
58CROIC22.8%A
Grade A: MoatNOPAT (EBIT less ~21% tax) / invested capital (equity + debt − cash). Flagship quality metric — durable >15% signals a moat
ROENeg. EquityC
Grade C: BuybacksReturn on Equity. Neg. equity = heavy buybacks
ROA4.7%D
Grade D: WeakReturn on Assets (Finnhub) — Net Income / Total Assets; how efficiently assets produce profit
Net Margin9.8%C
Grade C: AverageNet Income / Revenue
Operating Margin26.2%A
Grade A: HighTTM EBIT / TTM Revenue
Gross Margin71.5%A
Grade A: PremiumGross Profit / Revenue
FCF Margin28.3%A
Grade A: HighFCF / Revenue
True FCF Margin26.8%A
Grade A: HighTTM (OCF − CapEx − SBC) / TTM Revenue — SBC treated as a real cost
Growth
31DRevenue CAGR2.1%D
Grade D: LowCompound annual revenue growth (up to 5Y depending on data availability)
Net Income CAGR-22.2%D
Grade D: LowCompound annual net income growth (up to 5Y depending on data availability)
EPS CAGR (5Y)-22.2%D
Grade D: LowCompound annual EPS growth over up to 5Y of per-share earnings (own statements). Null when either endpoint EPS ≤ 0
Implied EPS Growth372.9%A
Grade A: HighAnalyst forward EPS (normalized basis) vs our GAAP TTM EPS — different bases, so extreme values usually mark cyclically depressed TTM earnings, not real growth
Dilution (5Y)-0.5%B
Grade B: FlatShare count change over 5Y
SBC / Net Income15.5%C
Grade C: MedStock-based comp/Net income. >30% = dilution risk
SBC / Revenue1.5%A
Grade A: LowTTM stock-based comp / TTM Revenue
Financial Health
39DAltman Z-Score2.37C
Grade C: Gray zoneBankruptcy risk. >3 Safe, <1.8 Distress
Current Ratio0.81xD
Grade D: LowCurrent Assets/Liabilities
Quick Ratio0.49xD
Grade D: Low(Current Assets − Inventory) / Current Liabilities (Finnhub) — stricter liquidity test, excludes inventory
Interest Coverage3.5xC
Grade C: OkEBIT/Interest. >10 Strong
Debt Repayment3.5yC
Grade C: AverageYears to repay net debt via FCF
Net Debt/EBIT3.8xC
Grade C: MedLeverage. <2x Low, >4x High
Debt/Equity—
Debt / Equity: <1 Conservative, >2 Risky. Not meaningful with non-positive equity; shown as unavailable rather than low debt.
Cash / Debt0.09xD
Grade D: ThinCash covers how much of total debt. >1 = could repay all debt from cash
Quality
95A+Piotroski F-Score8/9A
Grade A: StrongFinancial strength 0–9. >7 Strong
Beneish M-Score-2.85A
Grade A: SafeEarnings manipulation risk. < -2.22 Safe
FCF Conversion288.6%A
Grade A: StrongFCF / Net Income
Margin Stability7.0%A
Grade A: StableEBIT margin std deviation. Lower = stable
Capex / Revenue2.0%A
Grade A: Asset-lightTTM CapEx / TTM Revenue — high % = capital-hungry business
Asset Turnover0.48xD
Grade D: LowRevenue / Total Assets (Finnhub) — how efficiently the asset base generates sales
Insider Transactions
SEC Form 4 · 8 recordsP/S codes are the directional signal; grants, option exercises and tax withholding carry none. Form 4 doesn't flag 10b5-1 plans — scheduled sales may appear within open-market sells.
| Trade date | Insider | Transaction | Shares | Filed |
|---|---|---|---|---|
Quaggin Susan E Filed | Quaggin Susan E | Grant / award | +59 | |
RAPP EDWARD J Filed | RAPP EDWARD J | Grant / award | +129 | |
Donoghoe Nicholas Filed | Donoghoe Nicholas | Option exercise | -32710 | |
Donoghoe Nicholas Filed | Donoghoe Nicholas | SellOpen market sale | -32710 | |
Donoghoe Nicholas Filed | Donoghoe Nicholas | Option exercise | +32.7K |
Show 3 more filingsShow fewer filings
| Trade date | Insider | Transaction | Shares | Filed |
|---|---|---|---|---|
Quaggin Susan E Filed | Quaggin Susan E | Grant / award | +62 | |
RAPP EDWARD J Filed | RAPP EDWARD J | Grant / award | +134 | |
Quaggin Susan E Filed | Quaggin Susan E | Grant / award | +1.1K |
Option exercise (M) rows report a derivative leg, not an open-market sale — a paired negative entry is the option position being consumed.
More metrics — Moat, Per Share, Balance Sheet, MarketHide additional metrics
Moat
88AROIC >12% Years8/10 yrsA
Grade A: DurableShare of completed fiscal years with ROIC > 12% — measures multi-year capital-return durability
Gross Margin (Med.)70.1%A
Grade A: DurableMedian annual gross margin across available fiscal years — pricing-power durability
FCF-Positive Years10/10 yrsA
Grade A: DurableShare of completed fiscal years with positive free cash flow
Net Margin Floor6.9%A
Grade A: DurableWeakest annual net margin across completed fiscal years — recession/downcycle resilience
Per Share
EPS (TTM)$3.57
Own TTM net income / shares — same earnings basis as P/E
Cash / Share$3.72
Cash & short-term investments per share (Finnhub)
Book Value / Share$0.80
Shareholders' equity per share (Finnhub). Negative = accumulated losses / heavy buybacks
Balance Sheet
Total Debt$70.89B
Total debt obligations (short + long term)
Cash & Equiv.$6.57B
Cash and short-term investments
Net Debt$64.32B
Total Debt minus Cash. Negative = Net Cash position
Total Equity$-5.89B
Shareholders' equity (book value)
Asset / Liability0.96xD
Grade D: RiskyTotal Assets / Total Liabilities
Market
Market Cap$505.31B
Current Market Capitalization
Beta0.20B
Grade B: DefensivePrice sensitivity vs the market (Finnhub) — 1.0 moves with market, >1.2 amplifies swings
How grades work: each metric is graded A–D against fixed thresholds (tap a row for the meaning). Card grades map the pillar score to A+–E — a card grade is that pillar's own score, not an average of the rows shown.
Financials as of Jun 2026 · Ratio snapshot Oct 16, 2026
Key Insights: ABBVIE INC. (ABBV)
ABBV is up 0.71% at the last close. ABBVIE INC. meets 8 of 9 Piotroski F-Score criteria, placing its fundamental strength in the top tier of US-listed stocks. Altman Z-Score of 2.37 falls in the grey zone (1.81–2.99) — financial distress is unlikely but not ruled out. Beneish M-Score of -2.85 suggests a low likelihood of earnings manipulation.
- ABBVIE INC. converts about 28% of revenue into free cash flow — strong cash generation.
- Takes ~3.5 years to repay net debt from free cash flow.
- The stock currently yields 2.4% in dividends.
See how ABBV ranks on the Capex Tracker — top 50 capital spenders compared.
Recent Market Moves
See all ABBV moves →| Date | Session | Price | Move | Z-Score |
|---|---|---|---|---|
| Oct 14 | Regular | 282.80 | +3.08% | 2.81 |
| Oct 14 | After-hours | 284.83 | +3.82% | 3.53 |
| Oct 13 | Regular | 274.42 | -2.38% | -3.53 |
| Oct 13 | After-hours | 274.51 | -2.35% | -3.48 |
| Oct 12 | After-hours | 281.58 | +1.85% | 2.14 |
Frequently Asked Questions about ABBV
What is the current ABBVIE INC. (ABBV) stock price?
ABBV is trading at $285.42 at the last market close, up 0.71% on the session. PreMarketPrice tracks ABBV pre-market, intraday and after-hours prices.
Is ABBV stock a buy right now?
PreMarketPrice's quantitative model rates ABBVIE INC.'s financial health at 39/100. This is a data-driven snapshot of fundamentals, not investment advice.
Is ABBV stock overvalued?
ABBVIE INC. trades at a trailing P/E of 80.1 and our valuation score rates it 34/100 (higher = cheaper vs. its own history). See the Valuation History and Key Metrics sections for forward P/E, EV/EBITDA and PEG context.
When does ABBVIE INC. report earnings?
No confirmed earnings date is currently scheduled for ABBV. The Earnings section lists recent reports and updates as dates are announced.
What sector does ABBVIE INC. operate in?
ABBVIE INC. operates in the Healthcare sector, within the Drug Manufacturers - General industry. The Related Stocks section lists sector peers for comparison.
What does ABBVIE INC. do?
AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta).
About ABBVIE INC. (ABBV) Stock
ABBVIE INC. (ABBV) is a US-listed stock operating in the Healthcare sector, specifically the Drug Manufacturers - General industry. As of the latest update, ABBVIE INC. is trading at $285.42, up 0.71% on the day with a market capitalization of $505.3 billion. The financial health score for ABBV is 39/100, which indicates weak financial strength based on profitability, leverage, liquidity, and growth metrics. This page provides real-time pre-market pricing, earnings calendar, financial health analysis, and valuation metrics for ABBV stock.
ABBV Stock Analysis & Key Metrics
On PreMarketPrice, you can track ABBVIE INC. (ABBV) across multiple dimensions:
- Pre-market price & movement: Real-time ABBV stock price with percentage change, updated continuously during pre-market and regular trading hours.
- Valuation & P/E history: Historical P/E, P/S, and P/B ratios for ABBV with trend analysis and normalized valuation multiples.
- Financial statements: Revenue, net income, assets, liabilities, and equity for ABBVIE INC. across multiple reporting periods.
- Financial health score: A composite score of 39/100 based on Altman Z-Score, Piotroski F-Score, profitability, and leverage metrics for ABBV.
- Sector peers: Compare ABBV against 6 other healthcare stocks on key financial metrics.
Is ABBV a Good Stock to Buy?
This page provides data-driven analysis to help you evaluate ABBVIE INC. (ABBV) as an investment. The financial health score of 39/100 suggests weak financial fundamentals. Valuation metrics show whether the stock is trading above or below its historical average.However, this is not financial advice — always do your own research before investing.
Data on this page is sourced from real-time market feeds, Polygon.io, and Finnhub.ABBVIE INC. (ABBV) trades on NYSE/NASDAQ. Pre-market trading occurs 4:00 AM – 9:30 AM ET. Regular market hours are 9:30 AM – 4:00 PM ET.